Newamsterdam Pharma Stock Performance
| NAMS Stock | 18.49 1.26 6.38% |
The company secures a Beta (Market Risk) of 1.07, which conveys a somewhat significant risk relative to the market. NewAmsterdam Pharma returns are very sensitive to returns on the market. As the market goes up or down, NewAmsterdam Pharma is expected to follow. At this point, NewAmsterdam Pharma has a negative expected return of -0.27%. Please make sure to verify NewAmsterdam Pharma's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in July 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.28) | Five Day Return (3.28) | Year To Date Return (23.92) | Ten Year Return 86.11 | All Time Return 86.11 |
Last Split Factor 1:1 | Last Split Date 2022-11-23 |
1 | Acquisition by Kastelein Johannes Jacob Pieter of 150000 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 03/24/2025 |
2 | Disposition of 38394 shares by Davidson Michael H. of NewAmsterdam Pharma subject to Rule 16b-3 | 03/26/2025 |
3 | The Analyst Verdict NewAmsterdam Pharma Co In The Eyes Of 6 Experts - Nasdaq | 04/08/2025 |
4 | Disposition of tradable shares by Lange Louis G of NewAmsterdam Pharma subject to Rule 16b-3 | 04/14/2025 |
5 | Insider Trading | 04/15/2025 |
6 | Acquisition by Davidson Michael H. of 123529 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 04/25/2025 |
7 | NewAmsterdam Pharma Co NV Q1 2025 Earnings Revenue Surges to 3. ... | 05/08/2025 |
8 | Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 18.38 subject to Rule 16b-3 | 05/15/2025 |
9 | Acquisition by Douglas Kling of 165 shares of NewAmsterdam Pharma subject to Rule 16b-3 | 05/16/2025 |
10 | Wall Street Zen Downgrades NewAmsterdam Pharma to Sell | 05/23/2025 |
11 | Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.s CEO Compensation | 05/29/2025 |
12 | NewAmsterdam Pharma Coverage Initiated at Cantor Fitzgerald | 06/04/2025 |
13 | NewAmsterdam Pharma to Host RD Day on June 11, 2025 | 06/05/2025 |
14 | NewAmsterdam Pharma Co NV Announces Promising Phase 3 Trial Results for Alzheimers ... | 06/09/2025 |
15 | NewAmsterdam Pharma Company N.V. Analysts Just Trimmed Their Revenue Forecasts By 14 | 06/10/2025 |
16 | NAMS Needham Reiterates Buy Rating and Maintains Price Target NAMS Stock News | 06/12/2025 |
17 | NewAmsterdam Pharma Shares Bought by Handelsbanken Fonder AB | 06/13/2025 |
| Begin Period Cash Flow | 340.4 M |
NewAmsterdam | Build AI portfolio with NewAmsterdam Stock |
NewAmsterdam Pharma Relative Risk vs. Return Landscape
If you would invest 2,361 in NewAmsterdam Pharma on March 19, 2025 and sell it today you would lose (460.00) from holding NewAmsterdam Pharma or give up 19.48% of portfolio value over 90 days. NewAmsterdam Pharma is currently does not generate positive expected returns and assumes 3.8149% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than NewAmsterdam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NewAmsterdam Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NewAmsterdam Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NewAmsterdam Pharma, and traders can use it to determine the average amount a NewAmsterdam Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0709
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NAMS |
Estimated Market Risk
| 3.81 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NewAmsterdam Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NewAmsterdam Pharma by adding NewAmsterdam Pharma to a well-diversified portfolio.
NewAmsterdam Pharma Fundamentals Growth
NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (23.14) % | ||||
| Current Valuation | 1.46 B | ||||
| Shares Outstanding | 112.27 M | ||||
| Price To Book | 2.92 X | ||||
| Price To Sales | 48.13 X | ||||
| Revenue | 45.56 M | ||||
| Gross Profit | 47.14 M | ||||
| EBITDA | (241.49 M) | ||||
| Net Income | (241.6 M) | ||||
| Total Debt | 448 K | ||||
| Book Value Per Share | 6.93 X | ||||
| Cash Flow From Operations | (158.56 M) | ||||
| Earnings Per Share | (1.84) X | ||||
| Market Capitalization | 2.27 B | ||||
| Total Asset | 864.62 M | ||||
| Retained Earnings | (558.57 M) | ||||
| Working Capital | 756.5 M | ||||
About NewAmsterdam Pharma Performance
Assessing NewAmsterdam Pharma's fundamental ratios provides investors with valuable insights into NewAmsterdam Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the NewAmsterdam Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.32) | (0.30) |
Things to note about NewAmsterdam Pharma performance evaluation
Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NewAmsterdam Pharma generated a negative expected return over the last 90 days | |
| NewAmsterdam Pharma has high historical volatility and very poor performance | |
| NewAmsterdam Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 47.14 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: NewAmsterdam Pharma Shares Bought by Handelsbanken Fonder AB |
- Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
- Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.